Dr Anurag Saxena
Myfyriwr ymchwil, Cancer & Genetics, Yr Ysgol Meddygaeth
Mae'r cynnwys hwn ar gael yn Saesneg yn unig.
Trosolwg
Ymchil
Traethawd ymchwil
Neurocognitive function, brain structure and use of mTOR inhibitors in Tuberous Sclerosis
Cyhoeddiadau
2021
- Anurag, S. 2021. The effect of everolimus on neurocognitive aspects of tuberous sclerosis complex. PhD Thesis, Cardiff University.
2017
- Davies, M., Saxena, A. and Kingswood, J. C. 2017. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide. Orphanet Journal of Rare Diseases 12(1) (10.1186/s13023-017-0581-9)
2016
- Randell, E. et al. 2016. The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. Trials 17, article number: 398. (10.1186/s13063-016-1446-6)
2015
- Sampson, J. R. and Saxena, A. 2015. Epilepsy in tuberous sclerosis: phenotypes, mechanisms, and treatments. Seminars in Neurology 35(3), pp. 269-276. (10.1055/s-0035-1552616)
2014
- Saxena, A. and Sampson, J. 2014. Phenotypes associated with inherited and developmental somatic mutations in genes encoding mTOR pathway components. Seminars in Cell and Developmental Biology 36, pp. 140-146. (10.1016/j.semcdb.2014.09.018)